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Abstract
Objective: To study the pharmacodynamic and pharmacokinetic properties of oral and intravenous methylergometrine upon 
uterine motility during menstruation. Study-design: Intra-uterine pressure was measured in six volunteers with a fluid-filled sponge- 
tipped catheter during menstruation. Methylergometrine was given orally (0.5 mg) or intravenously (0.2 mg) in a cross-over design. 
Results: After intravenous administration, a fast increase of the frequency of uterine contractions and basal tone occurred with 
a decrease of amplitude, lasting at least 30 min. Oral administration had a late and less marked effect on uterine motility. An intra­
venous dose administered 24 h after an oral dose had no effect on uterine motility. Pharmacokinetic data, such as the maximum 
plasma concentration (Cmax), the time at which Cmax is reached (tmax) and the half-life of absorption a s^o demonstrated
large individual variations after oral administration. Conclusion: Oral administration of methylergometrine had an unpredictable 
and late effect on uterine motility on the menstruating uterus, probably due to an unpredictable bioavailability, in contrast with 
the fast and predictable effect after intravenous administration.
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1. Introduction
Uterine activity can be stimulated during menor­
rhagia or the postpartum period. Secale alkaloids were 
one of the earliest stimulants in obstetrics, applied as 
treatment or prevention of postpartum haemorrhage 
first noticed by Caspar Schwenkfeldt in 1600 [1]. In con­
trast to oxytocin and prostaglandins, secale alkaloids 
can be given orally, which has the advantage of easy 
drug administration. Pharmacokinetic and phar­
macodynamic data on oral secale alkaloids are, how­
ever, sparse.
Postpartum haemorrhage is responsible for 150 000 
deaths worldwide a year [2], -  98% of which occur in 
developing countries [3]. In these countries, active man­
agement of the third stage of labour with oxytocics is 
particularly advocated [4]. Intramuscular oxytocin, the
* Corresponding author.
standard care in the third stage, is not available to all 
women. Oral use of methylergometrine, although not 
recommended by the manufacturer, may be considered 
as an easy alternative. Before starting worldwide distri­
bution of these tablets, extensive studies on the stability, 
pharmacokinetic and pharmacodynamic parameters 
and clinical effects had to be performed.
This study simultaneously assessed pharmaco­
dynamic and pharmacokinetic parameters of oral and 
intravenous methylergometrine on uterine muscle in six 
non-pregnant women at the second day of the menstrual 
cycle (CD 2), because at CD 2 the menstruating uterus 
resembles the uterus in the postpartum period [5].
2. Materials and methods
2.1. Subjects
Six non-pregnant women with regular menstrual 
cycles volunteered for the pharmacokinetic and phar­
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macodynamic studies with methylergometrine. They 
were screened for possible contra-indications such as 
cardio-vascuar disease, chronic obstructive lung disease, 
fibroids or uterine surgery, and should have had a tubal 
ligation to prevent any negative interaction with fertili­
ty. This study was approved by the Committee for 
Experimental Research Involving Human Subjects 
(CEOM) of the University Hospital Nijmegen Sint Rad- 
boud, Nijmegen, the Netherlands.
2.2. Intra-uterine pressure (IUP) recordings
Intra-uterine pressure was recorded using a fluid-
filled sponge-tipped catheter [5,6], The portio vaginalis 
was cleansed and disinfected with iodine. The open-tip 
sponged catheter was inserted over a guiding tube. The 
uterus was manipulated as less as possible in order not 
to cause any interference with the uterine contractility 
pattern. A gauze was left in the vagina while the catheter 
was fixed on the upper leg to prevent expulsion. The 
catheter was connected to a pressure transducer, which 
was connected to a computer. The woman was in the 
supine position during the registration. The pressure 
transducer was fixed on the mattress, being the level of 
the surface supporting the supine volunteer. Zero pres­
sure was set at atmospheric pressure at this "mattress5 
level [7]. The location of the catheter was controlled by 
asking the volunteer to cough. Proper intra-uterine posi­
tion then showed a pressure elevation (about 10 mmHg).
Because the presence of any foreign body in utero 
causes an increase of basal pressure level for at least 20 
min [8], we waited 30 min to allow the ‘cyclic-specific* 
pattern to develop and then started the study. After re­
cording uterine activity at least 60 min after the insertion 
of the sponge-tipped catheter, methylergometrine was 
administered either intravenously or orally. The 
registration ended when the catheter was expelled. If the 
catheter remained in its position, it was removed after 5 
h. A trans-urethral catheter was inserted to provide con­
tinuous bladder drainage because filling of the bladder 
was reported to effect IUP [8].
2.3. Digitalization o f the signal (IUP)
The intra-uterine pressure signal was filtered by a 0.65 
Hz filter. Total noise with shortened impulse was 
measured over 15 min (mean ±  S.D. = 0.442 ± 0.084), 
which did not disturb the general activity pattern.
To obtain an accurate signal, the range of the mercury 
scale had been set to 0-150 mmHg. Measurements were 
made using the DTX/plus pressure transducer (Viggo- 
spectramed, Oxnard, California, USA) and a specially 
developed amplifier before the signal was fed to a per­
sonal computer (DASH-8, Metrabyte). Special care had 
been taken for patient safety using a safety chart. The 
software had been developed with Borland C++ (Scotts 
Valley, California, USA). Events were marked by spe­
cial keys. Recordings were stored in files which were
Microsoft Excel compatible. The resolution of the whole 
system was about 0.5 mmHg. The system was calibrated 
electronically and mechanically (mmHg).
2.4. Pharmacodynamics
Mechanical uterine activity was measured by IUP 
recordings. Contractions were expressed in IUP cycles. 
An IUP cycle was defined as a transitory rise above the 
basal tone. To describe uterine activity, IUP cycle- 
specific parameters were distinguished: frequency (F), 
basal tone (BT ), intensity (I) and amplitude 
(A = I  -  BT). The number of IUP cycles in a 5 min 
period were recorded and the mean value of F, BT  and 
A of the IUP cycles in each 5 min period were 
calculated,
The mean values of these parameters (F, BT  and A) 
during the 30 min registration of the ‘cyclic-specific5 pat­
tern were regarded as baseline values and set at 100%. 
For each parameter the relative increase in a 5 min 
period was expressed as a percentage of baseline value 
and plotted against time. For each IUP recording, the 
area under the curve (/i UQ  was calculated in time inter­
vals of 30 min from the time of drug administration until 
90 min after administration.
2.5. IUP recordings
Registration took place at the 2nd day of the cycle 
(CD 2) of two subsequent menstrual cycles to rule out 
a possible refractory period, i.e. uterine insensitivity to 
methylergometrine. In addition four women were also 
examined when 0.2 mg methylergometrine was injected 
on the third day of menstruation of the second cycle 
(CD 3), i.e. 24 h after the oral test.
2.6. Drugs
Pure methylergometrine (reference substance 108) 
was obtained from Sandoz Pharma AG (Basel, 
Switzerland). Methylergometrine maleate (0.125 mg tab­
let Methergin®; equivalent to 0.095 mg free base) was 
obtained from Sandoz Germany, Nürnberg; batch num­
ber 3001. Methylergometrine maleate (0.20 mg/ml injec­
table solution; equivalent to 0.152 mg free base) was 
obtained from Sandoz, Uden, The Netherlands; batch 
number 475 M FD  920812. These methylergometrine 
batches fulfilled the requirements of standard quality 
control criteria.
2.7. Dosage
Dosage A . For the assessment of the bioavailability of 
methylergometrine, a cross-over design was used for the 
intravenous and oral administrations. The interval be­
tween both administrations was one menstrual cycle. An 
intravenous dose of 0.2 mg methylergometrine maleate 
was injected at CD 2 after a standard breakfast contain­
ing two sandwiches, no cheese and unrestricted amounts 
of coffee or tea by all subjects. The drug was ad­
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ministered at least 1 h after insertion of the IUP 
catheter. Care was taken that all of the intravenous dose 
was administered by cleaning the intravenous dosage 
line with 2 ml 0.9% saline. An oral dose of 0.5 mg 
methylergometrine maleate was given after a standard 
breakfast on the second day of the next menstrual cycle.
Dosage B. An additional intravenous administration 
was administered in four women on CD 3, 24 h after 
oral administration at CD 2.
2.8. Sampling
Oral administration. Blood samples of 5 ml were col­
lected through an intravenous (IV) internal catheter 
(Venflon® 1.0 mm OD) in tubes containing 0.5 mg Li 
heparin at 0, 10, 20, 30, 60, 90, 180 and 240 min.
Intravenous administration. Intravenous administra­
tion of methylergometrine took place for 1 min in the 
opposite arm to where the Venflon was located. In addi­
tion to the sampling times as described under oral ad­
ministration, two extra samples were taken at 3 and 5 
min after the start of the injection. After centrifugation 
of the blood samples at 11 000 g for 5 min, plasma sam­
ples from both the oral and intravenous groups were 
stored at -20°C pending analysis.
2.9. Drug analysis
Drug analysis was performed by High Pressure Liq­
uid Chromatography (HPLC) according to de Groot et 
aL [9].
2.10. Pharmacokinetic analysis
The pharmacokinetic parameters were calculated 
from a two-compartment model after intravenous ad­
ministration, and from a one-compartment model with 
lag-time fitted to oral data (MW/Pharm computer pro­
gram, Mediware®, Groningen, the Netherlands) [10]. 
Cmax is the maximum plasma concentration read from 
the fitted plasma concentration-time curve (r2 >  0.98), 
and tmax the time at which Cmax occurs. The ¿^-values 
were calculated from ln(2)//3, where /3 is calculated by 
log-linear regression analysis of the terminal log-linear 
phase. The tJ/2absorption and tJ/2oi were obtained by line 
feathering and linear regression analysis.
Mean absorption time (MAT) was used as a measure 
o f  the rate of absorption and calculated as the difference 
between (M RTpo -  tlag) and M RTiv.
AUC0^ « is the area under the plasma concentration­
time curve and was calculated using the linear 
trapezodial rule with extrapolation of / = oo, using C,//3 
with Ct being the last measured concentration. The 
bioavailability (F) is AUCora}• Doseiv / AU Civ*Doseora!. 
Total body clearance, CL = F-Dose I AUC0^ œ. Vss is 
the volume of distribution in steady state (Vss = F* 
DosB'AUMCq^o, / AUCq^oo2)- Analyses of variance
were conducted according to standard procedures. The 
level of significance was defined as P  = 0.05.
3. Results
3.1, Subjects
Six women entered the study. Their mean age was 
38 =fc 5 years, mean weight 59 ±  5 kg and mean length 
167 db 6 cm (mean ± S.D.). The blood pressure ranged 
between normal values; mean systolic pressure 
113 =fc 11 mmHg, mean diastolic pressure 73 ±  8 
mmHg. They all had a uterus in an anteversion- 
anteflexion position.
3.2. Pharmacokinetic results
Table 1 summarizes the mean pharmacokinetic par­
ameters of 0.2 mg methylergometrine after intravenous 
administration and of 0.5 mg after oral administration
m
in the six women at CD 2. After intravenous administra­
tion, the distribution half-life (t}/2ct) was 0.09 ±  0.04 h. 
The elimination half-life ( t ^ )  was 2.0 ±  0.3 h. The 
total body clearance (CL) amounted to 22.0 ± 2 .7  1/h
Table 1
Pharmacokinetic parameters (mean ±  S,D.) of methylergometrine 
after intravenous 0,2 mg (0.152 mg base) and oral 0.5 mg (0.380 mg 
base) administration in six female volunteers
Intravenous Oral Significance
( n
Dose (mg) 0.152 0.380
F (%) 74.2 ±  18.5
hag (h ) 0.30 ±  0.08 i
*max (h ) 0.75 ±  0.40
Cm axfa  S'1) 3.88 ±  2.19
l I/2abs 0^) 0.14 ±  0,12
W  (h) 0.09 ±  0.04
2.0 ± 0.3 1.6 ±  0.3 0.0855
M RT  (h) 2.3 ± 0.4 2.8 ±  0.4 0,0855
MA Th (h) 0,40 ±  0,35
AUCo~«(pfrhn) 6,2 0.57 9.6 =fc 4,8
CL (1/h) 22.0 ±  2.7 30,0 dfc 8.8 0,0607
yu ® 50.5 ± 5.8 68.6 ±  24.0 0.1048
“One-compartment; bmodel independent;------- , not detected.
Bioavailability (F), AUCorar Doseivf AUCiv• Doseoraf, i!ag (h), lag 
time; tmax (h), the time at which Cmax occurs; Cmax (jig/1), the maxi­
mum plasma concentration read from the plasma-concentration-time 
curve; t ¡/2abs (h), the half-life of absorption, calculated by least-square 
linear regression analysis; ty2a (W* the half-life of distribution, 
calculated by least-square linear regression analysis; ty2$ (h), the half- 
life of elimination, calculated by least-square linear regression analy­
sis; M RTiv (h), the mean residence time AUMC/AUC  after intrave­
nous administration; AiAT(h)> the mean absorption time, difference 
between (MRTpo -  t(ag) and M R T -^ A V C ^ ^  0*g-h/l), the area under 
the plasma-concentration-time curve extrapolated to infinite time; CL 
(1/h), total body clearance, Dose/AUC^^; Vss (1), the volume of dis­
tribution in steady state (Kw = Dose*AUMC0^ oa / AUCq^ ^ 2).
104 A.N J.A . de Groot et al /European Journal of Obstetrics & Gynecology and Reproductive Biology 60 (1995) 101-107
Table 2
Pharmacokinetic parameters (mean ±  S.D.) in four females
A B Significance
(P)
{!/2a (h) 0.09 =fc 0.04 0.05 ±  0.02 0.14
h/2fi (h) 2.0 ±  0.3 1.9 ±  0.5 0.78
MR Tiv (h) 2.3 ±  0.4 2.2 db 0.6 0.65
AUC0^ 6.2 =fc 0.6 7.0 ±  3.1 0.55
fog • h/l)
CL (1/h) 22.0 st 2.7 24,0 db 9.3 0.63
v„ (/) 50.5 ±  5.8 49.8 ±  15.9 > 0.8
A, intravenous methylergometrine (ME) (0,2 mg) without preceding 
oral ME; B, intravenous ME (0.2 mg) with preceding oral ME (0.5 
mg).
Abbreviations: see Table 1.
and the steady state volume of distributipn ( Vss) was 
50.5 ±  5.8 1/h. After oral administration of methyl­
ergometrine, the lag time was 0.30 ±  0.08 h, the absorp­
tion half-life (tj/2abs) was 0-14 ±  0.12 h, the’ mean 
absorption time {MAT) was 0.40 ±  0.35 h and the 
elimination half-life (tj/2p) was 1.59 =t 0.32 h. Total 
body clearance was 30.0 ±  8.8 1/h and the volume of 
distribution was 68.6 ±  24 1. The biovailablity (F) was 
subject dependent and ranged between 47.7% and 
94.6%, with the assumption that the total body 
clearance is similar after intravenous and oral adminis­
tration. Large inter-individual differences in Cmax (53% 
C.V.), tmax (56% C.V.) and tmabs (85% C.V.) after oral
administration were recorded. Two volunteers showed 
prolonged absorption and were left out in the calcula­
tion of the means.
Table 2 summarizes the pharmacokinetic parameters 
after additional intravenous administration of 0.2 mg 
methylergometrine in four women when it was injected 
on CD 3 of the second cycle, i.e. 24 h after the oral ad­
ministration. There is no difference in pharmacokinetic 
parameters after the intravenous dosage at CD 2 of the 
first menstrual cylce and at CD 3 of the second cycle (P 
> 0.05).
3.3, Pharmacodynamic results — effect of 
methylergometrine on IUP
When 0.2 mg methylergometrine was injected in­
travenously on CD 2 of the first menstrual cycle, the fre­
quency of uterine contractions and basal tone increased 
in all six women, while the amplitude of the uterine con­
tractions decreased. This effect lasted at least 90 min 
with a maximum at 30 min. Within one woman the 
effect of 0.5 mg oral methylergometrine on uterine activ­
ity on CD 2 of the second menstrual cycle was much less 
marked than after the intravenous administration.
Fig. 1 shows the effect of methylergometrine on IUP 
in volunteer 1. At the top of the figure the IUP recor­
dings after intravenous (left panel) and oral (right panel) 
administrations are given. At the bottom the mean 
values of F, B T  and A of the IUP cycles over 5 min 
periods are shown.
The left panel shows the fast increase in frequency,
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Fig. 1. Effect of methylergometrine (ME) after intravenous (0.2 mg) (left) and oral (0.5 mg) (right) administration in one representative volunteer. 
At t = 0, ME was administered. Top-tracing: Effect on intra-uterine pressure. Bottom-tracing: Effect on frequency (F), basal tone (BT) and 
amplitude (/i). The mean values o f F, BT  and A during 30 min before drug administration were regarded as baseline values and set at 100%» the 
increase in a 5 min period was expressed as a percentage of baseline value and plotted vs. time after intravenous (0.2 mg) ME and oral (0.5 mg) 
ME administrations.
A .N J .A . de Groot et al /  European Journal o f Obstetrics Gynecology and Reproductive Biology 60 (1995) 101-107 105
A B
Mean Basal Tone
mm Hg
T
30
"T
60
n=6
n=4
IUP n/5min
Mean Frequency
4
n=6
0 X30 I
- p
30 I r
mmHg
Mean Amplitude
-« n=4
Time (minutes)
Fig, 2. Mean basal tone (BT), mean frequency (F) and mean amplitude 
(A) of intra-uterine pressure (IUP) cycles in a 5 min period vs. time. 
At t = 0> methylergometrine (ME) was administered. A, left panel: The 
effect of intravenous (0,2 mg) and oral (0.5 mg) administrations of ME 
on mean B T (mmHg), mean F  (number of IUP/5 min period = IUP n/5 
mm) and A (mmHg) of IUP cycle in a 5 min period, in menstruating 
women (rt = 6). B, right panel: The effects of 0.2 mg ME on the same 
parameters are shown without (n = 6) and with (n = 4) 0.5 mg ME 
given orally 24 h before the intravenous administration.
basal tone and decrease in amplitude of uterine contrac­
tions after intravenous administration of 0.2 mg 
methylergometrine. Within 3 min after the injection, the 
frequency of contractions increased by 350% to a maxi­
mum of 650% as a percentage of the baseline frequency 
value. After 35 min the increase of frequency was
reduced to 200% of the baseline value. The basal tone 
showed a fairly identical pattern with a maximum 
increase o f 700% within 10 min after drug administra­
tion. Basal tone remained increased to 550% of its base­
line value until 70 min after drug administration. The 
amplitude decreased to 30% of its baseline value within 
10 min and remained reduced during further recording.
The right panel shows the late and less marked effect 
after oral administration of 0.5 mg methylergometrine. 
An increase in frequency of 240% occurred 35 min after 
drug administration. A maximum increase of 320% of 
the baseline value was reached after 50 min. An increase 
in basal tone was seen after 30 min with maximum 
values of 700% after 50 min. The basal tone remained 
elevated compared to the baseline values. The amplitude 
decreased to 17% after 55 min, but returned to its base­
line value 80 min after drug administration.
Fig, 2 illustrates the mean frequency, mean basal tone 
and mean amplitude in 5 min periods after oral and in­
travenous administratios (A, left panel) and after intra­
venous administration at CD 2 and the day after an oral 
test CD 3 (B, right panel). The values used in the figure 
are the mean values of the 6 volunteers.
The figure clearly illustrates the different patterns in 
F, BT  and A after intravenous or oral administrations 
(left panel). It also shows that there is hardly any uterine 
response to a 0.2 mg intravenous dose if this is preceded 
by 0.5 mg methylergometrine 24 h before (right panel).
Table 3 shows the A UC of the individual IUP record­
ings, When AUC  30 min before drug administration 
(AU C^q^ o) is compared to AUC  30 min after drug 
administration (AUC0^ 30), a marked increase in AUC  
is seen after intravenous administration and hardly any 
after oral administration. After oral administration, a 
(slight) change in A UC is seen in the period between 30 
and 60 min after the intake of 0.5 mg methyl­
ergometrine.
When 0.2 mg methylergometrine was injected 24 h 
after the oral test, hardly any changes in B T , F  and A 
of intra-uterine pressure were recorded (Fig, 2B). The 
A UC was less increased than after the injection of 0.2 
mg methylergometrine at CD 2 of the first menstrual 
cycle and even less than after the oral administration of 
0.5 mg methylergometrine (Table 3).
3.4. Side effects
Three women experienced dizziness after intravenous 
injection, while all experienced abdominal cramps 
within 5 min after intravenous administration. After an 
oral dose, three out of six experienced abdominal 
cramps approximately 1 h after drug administration.
4. Discussion
This study demonstrates the feasability of assessing 
the effect of uterine stimulation during human menstru-
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Table 3
Area under the curve during several time periods in relation to administration of methylergometrine (ME) intravenously (0.2 mg) and orally (0.5 mg)
Volunteer
I 2 3 4 5 6
A (without preceding oral ME)
Intravenous
A t/C_3O-0 726 843 1456 1320 339 682
A UC0~ so 2163 1329 2042 2384 580 943
A UCiQ-60 1829 1352 1119 1479 651 914
A U çq 1725 1311 857 1764 236 650
A UCq^ qq 5717 3992 3018 5627 1467 2507
Oral
AUC„30^q 640 1209 1077 1420 1062 1453
A UC0_ 30 857 1240 1018 1320 953 998
A UC30- 6O 1857 1307 1205 1851 1249 736
AUC6Q^QQ 1358 1330 1216 1944 1244 1627
AUCq^ çq 4072 3883 3439 5115 3446 3363
B (with preceding oral MEa)
Intravenous
A U C ^ o 365 474 872 971 ---------
AU Co-, so 111 384 805 782 --------- ----------
AUC3q^ 60 719 460 731 984 --------- ----------
AUCgQ^ QQ 541 426 719 1294 --------- ----------
AUCq^ çq 2037 1270 2255 3060 ---------- ----------
A UC, area under the curve, calculated by ElUP/sampIe points x time (min). 
A UCo-+3o> AUC over a time period from 0-30 min after drug administration. 
aOral ME 24 h before intravenous administration.
ation with pharmacokinetic data. Although uterine 
stimulation is not frequently used to treat menorrhagia, 
this model may provide indirect evidence for the more 
important issue of postpartum haemorrhage. It is likely 
that the human uterus functions similarly during men­
struation and labour, i.e. in providing an expelling force. 
This can be demonstrated by the intra-uterine pressure 
patterns, which are similar in both situations [5,11,12]. 
The same holds true for coagulating and fibrinolytic 
properties within the uterine cavity [13,14].
It is also our experience that the method used in this 
study, i.e. the sponge-tipped fluid-filled catheter, is more 
reliable in the non-pregnant uterus than in the postpar­
tum uterus because of the increased degree of expulsion 
in the latter. In the postpartum uterus, only trans- 
abdominally placed open-tip catheters are thought to 
provide the most reliable quantative information on 
uterine contractility. This procedure, however, en­
counters medical and ethical contra-indications when 
used just for research purposes. Micro-transducers at 
the catheter tip were not used because of possible ar­
tifacts [15] and the impossibility of calibration during 
the recording [16].
The most striking observation was the wide variation 
of bioavailability of oral methylergometrine, which cor­
responds with the recently published data found in male 
volunteers [9]; former data on methylergometrine [17]
described only a fast absorption of methylergometrine
tablets.
Uterine motility was reflected in BT , F, A and AUC  
of the IUP cycle. The values of two AUC_30^ 0 in the 
same volunteers in different tests were not similar which 
makes it irrational to compare AUC0_90 after intra­
venous and oral administrations within the same 
volunteer (e.g. volunteer 5). In one volunteer (volunteer 
5), F, B T  and A  showed quantitative variations at CD 
2 of two subsequent menstrual cycles before administra­
tion of methylergometrine. This explains why differ­
ences in AUC„30^ q existed in the subsequent menstrual 
cycles in one volunteer. Volunteers 3, 5 and 6 (Table 3) 
had a higher B T  before oral administration than before 
the injection of methylergometrine. This explains why 
A UCq^ m is larger after oral than intravenous adminis­
tration. The changes in BT , F, A  and AUC  after oral ad­
ministration of methylergometrine show a rather late 
and unpredictable stimulating effect on uterine motility. 
They reflect the same wide variation as observed in the 
pharmacokinetic data after oral administration.
The observation of the strongly diminished effect of 
intravenously-administered methylergometrine 24 h 
after oral administration suggests a long-lasting receptor 
blockade. It seemed as if the uterus was insensitive to the 
methylergometrine dose. The first dose may affect and 
change the uterine receptors for methylergometrine.
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This could explain the insensitivity to the second dose of 
0.2 mg methylergometrine in postpartum uteri lasting 3 
h, measured by external tocography as reported in 1959 
[18] and observed in our experiments even 24 h after 
oral administration of 0.5 mg methylergometrine, 
Methylergometrine probably blocks a-receptors in the 
inner layer, specifically affecting the basal tone of this
layer [19-21].
S. Conclusion
Oral administration of methylergometrine shows a 
late and unpredictable effect on the menstruating uterus 
in contrast to the fast and predictable effect of an intra­
venous dose. A relation between plasma concentration 
and pharmacodynamic effect could not be demonstrated 
after oral administration. Therefore, oral secale alka­
loids cannot be advocated for either the treatment of 
menorrhagia or for postpartum haemorrhage.
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